Month: September 2026

Topline durability data reinforce potential for single-dose miv-cel to free patients from life-long disease burden and chronic immunotherapies, further highlighting miv-cel’s differentiated construct

Sustained clinical benefit and reversal of disability through one year support the potential to be the first approved therapy in SPS and first approved CAR T-cell therapy for autoimmune disease; rolling BLA submission on track for completion in Q4 2026

Longer-term Phase 2 follow-up in gMG demonstrate robust and durable effects sustained for up to 1.5 years, with majority of patients maintaining MSE;
Phase 3 enrollment expected to be completed in mid-2027

Consistent, well-tolerated safety profile with no high-grade CRS or ICANS, and no cases of IEC-HS in one-year follow-up

Company to host conference call on September 24, 2026 at 8 am ET

EMERYVILLE, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced positive one-year topline data from KYSA-8, its registrational trial of miv-cel (mivocabtagene autoleucel, KYV-101) in patients with stiff person syndrome (SPS), and positive topline longer-term follow-up data from the Phase 2 portion of KYSA-6, its registrational trial in patients with generalized myasthenia gravis (gMG). Data from both trials will be shared at upcoming medical meetings.

“The durable clinical responses achieved in SPS and gMG, combined with a consistently favorable safety profile, set a new benchmark for autoimmune CAR T and reinforce miv-cel’s potential best-in-class profile and ability to transform the treatment landscape across neurologic autoimmune diseases,” said Warner Biddle, Chief Executive Officer of Kyverna Therapeutics. “These one-year SPS data further strengthen our rolling BLA submission, which is on track to be completed in the fourth quarter of this year. Miv-cel’s differentiated construct and well-established manufacturing process underpin these longer-term results and highlight the opportunity to deliver one-time transformative therapies for people living with serious neurologic autoimmune conditions.”

“The results from KYSA-8 are compelling, particularly given the severe burden of SPS and the absence of approved therapies,” said Amanda Piquet, M.D., FAAN, Director of Autoimmune Neurology at the University of Colorado Anschutz School of Medicine, Céline Dion Foundation Endowed Chair, and lead investigator of the KYSA-8 trial. “After a single dose of miv-cel, the sustained improvements observed in mobility, stiffness and other disease-specific measures, together with a well-tolerated profile, underscore its potential to deliver significant, long-lasting benefit to patients with SPS.”

Topline 12-month Data in KYSA-8 SPS Registrational Trial

As reported at AAN 2026, the primary endpoint and all key secondary endpoints were achieved with statistical significance in KYSA-8. The topline one-year durability data further strengthen the positive results.

As of a database lock in July 2026, 12-month follow-up data on 26 patients with SPS include:

• Significant timed 25-Foot Walk (T25FW) improvement sustained at month 12 (p < 0.0001): median improvement from baseline of 46% at week 16 and 49% at month 12
• 95% of patients who achieved a clinically meaningful improvement (>20% reduction from baseline) at the primary analysis sustained their benefit
• Over one-third of patients completed T25FW in <5 seconds, comparable to a typical time for healthy adults
• Of the 12 patients requiring a walking aid prior to treatment, 67% continue to not require assistance
• Significant improvements in secondary endpoints remained consistent at 12 months (p values between <0.0001 and 0.0003)
• 92% of patients remained free of chronic immunotherapies for SPS
• Miv-cel continued to be well-tolerated with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS), and no cases of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS).

Kyverna intends to include the one-year data in its rolling Biologics License Application (BLA) submission, which is on track to be completed in Q4 2026. The full data set will be presented at MS Toronto, the joint ACTRIMS-ECTRIMS meeting, taking place October 21–23, 2026, in Toronto, Canada.

“In SPS, we continue to see powerful evidence that a single dose of miv-cel has the potential to reset the immune system, reverse disease progression, and free patients from chronic immunotherapies, delivering sustained clinical benefit and a well-tolerated safety profile,” said Naji Gehchan, M.D., Chief Medical and Development Officer of Kyverna Therapeutics. “Similarly, clinically meaningful responses were sustained to at least one year in our Phase 2 gMG trial, with nearly all patients remaining off immunosuppressant therapies. These unprecedented outcomes, combined with miv-cel’s differentiated profile as a fully human CD19 CAR T-cell therapy with CD28 co-stimulation, distinguish miv-cel from both approved and investigational treatments, and strongly support our ongoing Phase 3 registrational trial. Most importantly, they bring us closer to our goal of delivering durable, drug-free, disease-free remission for patients living with neurologic autoimmune diseases.”

Longer-term Follow-Up Data in KYSA-6 Phase 2 Trial in gMG

As of data cut-off in June 2026 (n=7), follow-up now extends one year and beyond (up to 1.5 years) in five patients, with one patient at 9 months and another at 6 months. Further strengthening the data shared at AAN 2026, a single dose of miv-cel led to deep and durable clinical responses, demonstrating:

• All 7 patients (100%) achieved clinically meaningful improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG), co-primary endpoints of the ongoing Phase 3 portion, at 24 weeks, with mean reductions of -8.3 and -11.7 points, respectively
  • Clinically meaningful improvements in MG-ADL, QMG and Myasthenia Gravis Composite (MGC) scores maintained through one year or longer in all five patients who have reached this time point
• Minimal symptom expression (MSE; defined as an MG-ADL score of 0 or 1) maintained in 57% of patients as of last follow up
• All 7 patients (100%) remained free of immunotherapies for MG, including nonsteroidal immunosuppressive therapies, high-dose steroids (>10 mg), and FcRn and complement inhibitors at 24 weeks, with 6 of 7 patients (86%) remaining off immunosuppressants as of last follow-up.
• Miv-cel continued to be well-tolerated, with no high-grade CRS, no ICANS, and no cases of IEC-HS.

Additional longer-term follow-up data from the Phase 2 portion of KYSA-6 will be shared in an oral presentation at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting on September 29, 2026, at 10:15 am EDT in Orlando, Florida.

The Phase 3 portion of the KYSA-6 trial is ongoing, with enrollment expected to be completed in mid-2027.

Investor Conference Call Details

Kyverna will host a conference call on Thursday, September 24, at 8 am ET to review the topline SPS and gMG longer-term follow-up data from KYSA-8 and KYSA-6, respectively. The conference call and live webcast details and presentation materials will be available on the “Events & Presentations” section of Kyverna’s Investor Relations webpage at ir.kyvernatx.com. An archived replay will also be available.

Dial-In Registration Link:
Conference Call Registration

Webcast Link:
Kyverna SPS and gMG Longer-Term Follow-Up Data Conference Call

About KYSA-8 Registrational Clinical Trial
KYSA-8 is a single-arm registrational Phase 2 trial in which 26 adult patients with SPS, who had an inadequate response to at least one immunotherapy treatment, received a single dose of miv-cel. The primary endpoints are the change from baseline in the T25FW at 16 weeks and the incidence and severity of adverse events (AEs). Secondary endpoints measuring disability, stiffness, hypersensitivity, and mobility include the Modified Rankin Scale (mRS), Distribution-of-stiffness Index (DSI), Heightened Sensitivity Scale (HSS), and Hauser Ambulation Index (HAI), respectively.

About KYSA-6 Phase 2/3 Clinical Trial
The Phase 2 portion of the KYSA-6 registrational trial is designed as a single-arm, open-label, multicenter study of miv-cel in patients with gMG. The primary efficacy endpoint is the change from baseline in MG-ADL score at 24 weeks and secondary endpoints include change from baseline in QMG and MGC scores at 24 weeks. Seven patients with moderate to severe gMG, all of whom had failed prior immunosuppressant therapies including FcRn and complement inhibitors, received a single dose of miv-cel.

The Phase 3 portion of the trial is a ~60-patient, global, open-label, randomized controlled trial with crossover design evaluating miv-cel versus standard of care (SOC). The co-primary endpoints are MG-ADL and QMG and the secondary endpoints include MGC change from baseline at 24 weeks compared to SOC, proportion of patients with a ≥3 point improvement from baseline in MG-ADL at 24 week compared to SOC, and the proportion of patients with MSE at 24 weeks compared to SOC. The Phase 3 trial is expected to complete enrollment by mid-2027.

About Stiff Person Syndrome (SPS)
SPS is a rare, progressive neurologic autoimmune disease characterized by muscle stiffness and painful muscle spasms, impacting mobility and gait. Stiffness, rigidity, and spasms in the torso, arms, and legs lead to progressive disability causing up to 80% of patients to lose mobility, requiring walking aid assistance or wheelchair use^1-3. SPS has been shown to lead to permanent disability and increased risk of mortality³. Most patients with SPS have antibodies to glutamic acid decarboxylase 65 (GAD65) or the glycine receptor, which disrupt normal inhibitory neurotransmission, contributing to the hallmark symptoms of SPS. There are currently no FDA-approved treatments for SPS. Current treatment options include symptomatic treatments, off-label immunotherapies, such as intravenous immunoglobulin (IVIg), rituximab and plasmapheresis, as well as supportive care and physical, speech, occupational, and psychiatric therapy; however, the majority of patients have inadequate or no response to these treatment options. An estimated 6,000 patients are diagnosed with SPS in the United States^4-5.

About Generalized Myasthenia Gravis (gMG)
Myasthenia gravis is a B-cell and antibody-mediated autoimmune neuromuscular disease that causes muscle weakness and fatigue, and patients may experience difficulty speaking, chewing, swallowing, or breathing.^6-7 MG is caused by autoantibodies produced by B-cells that lead to an immunological attack on critical signaling proteins at the junction between nerve and muscle cells, thereby inhibiting the ability of nerves to communicate properly with muscles. The disease includes gMG, which impacts muscles beyond the eyes and may involve bulbar, limb, and respiratory muscles. Most patients with ocular manifestations, the most common presenting symptoms, develop gMG within two years after MG diagnosis. Although symptoms may initially remit, most patients experience progressive disease requiring chronic immunosuppressive therapy. Up to 20% of MG patients experience respiratory crisis at least once in their lives.⁸ An estimated 80,000 patients are diagnosed with gMG in the United States.^9-10

About miv-cel (mivocabtagene autoleucel, KYV-101)
Miv-cel is a fully human, autologous, CD19-targeting CAR T-cell therapy with CD28 co-stimulation. It is uniquely designed for potency and tolerability with the potential to achieve deep B-cell depletion, reset the immune system and deliver durable drug-free, disease-free remission in autoimmune diseases with a single dose. Miv-cel is under investigation for B-cell driven autoimmune diseases and is produced using a well-established, validated manufacturing process. To date, more than 100 patients have been treated with miv-cel across a range of autoimmune diseases, and the clinical data demonstrates a consistent and well-tolerated safety profile.

About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a late-stage clinical immunology company pioneering differentiated therapies with curative potential for neurologic autoimmune diseases. Kyverna’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently completed registrational trial in stiff person syndrome (SPS) and an ongoing registrational trial for generalized myasthenia gravis (gMG).

Miv-cel has received three FDA Regenerative Medicine Advanced Therapy (RMAT) designations, in SPS, gMG, and non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further reinforcing the therapy’s potential across neuroimmunology. Additionally, the Company continues to advance new innovations that broaden access and choice for patients, expanding its leadership position in the field. For more information, please visit https://kyvernatx.com.

Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: the potential for a single dose of miv-cel to free patients from life-long disease burden and chronic immunotherapies, reset the immune system, reverse disease progression and deliver significant, long-lasting or sustained clinical benefit for patients with SPS; miv cel’s potential best-in-class profile; the potential for miv-cel to transform the treatment landscape across neurologic autoimmune diseases; the possibility that miv-cel may be the first approved treatment for patients with SPS or the first approved CAR T-cell therapy for autoimmune disease; the anticipated timing of the completion of the rolling BLA submission for miv-cel in SPS and data expected to be included in such submission; the expected timing of completion of enrollment in the Phase 3 portion of the KYSA-6 trial in gMG; Kyverna’s pipeline opportunities; and Kyverna’s potentially first-in-class neuroimmunology franchise. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions; risks related to the timing and outcome of regulatory submissions and interactions with the FDA; the ability to enroll patients in clinical trials on anticipated timelines; the possibility that topline results may change following further analysis or differ from final results; the possibility that results from prior clinical trials, named-patient access activities and preclinical studies may not necessarily be predictive of future results; and other factors discussed in the “Risk Factors” section of Kyverna’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna’s management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact:
Investors: InvestorRelations@kyvernatx.com
Media: media@kyvernatx.com

¹ Rakocevic G, et al. BMC Neurol. 2019;19:1.
² Dalakas MC. Nat Rev Neurol. 2024;20(10):587-601.
³ Duddy ME, Baker MR. Front Neurol Neurosci. 2009;26:147-165.
⁴ Crane PD, et al. Neurology. 2024;103(12):e210078.
⁵ Analysis of 2024 Komodo U.S. Claims Data.
⁶ Dresser L, et al. J Clin Med. 2021;10(11).
⁷ DeHart-McCoyle M, et al. BMJ Med. 2023;2(1): e000241.
⁸ Claytor B, et al. Muscle Nerve. 2023;68(1):8-19.
⁹ Rodrigues E, et al. Muscle Nerve. 2024;69(2):166-171.
¹⁰ Ye Y, et al. Front Neurol. 2024; 15:1339167.

LA JOLLA, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the completion of the last patient, last visit (LPLV) in the double-blind portion of COMBAT-ALS, a Phase 2b/3 clinical trial evaluating MN-166 (ibudilast) for the treatment of Amyotrophic Lateral Sclerosis (ALS). A total of 234 participants were randomized to two treatment arms at clinical sites in the United States and Canada. Participants who remain active in the study are continuing treatment with MN-166 in the Open-Label Extension phase. The LPLV for the entire study is expected in March 2027. MediciNova expects to report topline results from the double-blind portion of the study by the end of 2026.

MN-166 (ibudilast) is an orally administered small molecule designed to modulate neuroinflammation and oxidative stress pathways implicated in ALS progression. COMBAT-ALS is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy, safety, and tolerability of MN-166 during a 12-month double-blind treatment period, followed by a 6-month open-label extension.

The trial’s primary endpoint is the Combined Assessment of Function and Survival (CAFS). Secondary endpoints include change in the ALS Functional Rating Scale–Revised (ALSFRS-R), muscle strength measured by hand-held dynamometry, and quality-of-life assessments.

MN-166 has demonstrated a favorable safety profile in prior Phase 1/2 and Phase 2 clinical studies, with earlier studies also showing a higher proportion of treatment responders among participants who received MN-166. MN-166 has received Fast Track designation and Orphan Drug designation from the U.S. Food and Drug Administration (FDA), as well as orphan designation from the European Medicines Agency (EMA).

Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova, commented: “Completion of the last patient’s final visit in the double-blind portion of COMBAT-ALS marks a significant milestone for our lead clinical program and keeps us on track to report topline results by the end of 2026. With all patient visits now complete in the double-blind portion of the study, our focus is on database lock and rigorous analysis of the study data. We believe COMBAT-ALS has the potential to provide important insight into MN-166 as a treatment option for people living with ALS, a disease with substantial unmet medical need. We are deeply grateful to the participants and their families, caregivers, and care partners, as well as the investigators and clinical site teams whose commitment made this milestone possible.”

About MN-166 (ibudilast)

MN-166 (ibudilast) is a small-molecule compound that inhibits phosphodiesterase type 4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (MS), and degenerative cervical myelopathy (DCM). MN-166 is also in development for glioblastoma, Long COVID, chemotherapy-induced peripheral neuropathy (CIPN), and substance use disorder. In addition, MN-166 has been evaluated in patients at risk of developing acute respiratory distress syndrome (ARDS).

About MediciNova

MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has numerous programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in late stage trials for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants.

Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166 and MN-001. These forward-looking statements may be preceded by, followed by, or otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “estimates,” “projects,” “can,” “could,” “may,” “will,” “would,” “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166 and MN-001, and risks of raising sufficient capital when needed to fund MediciNova’s operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova’s collaborations with third parties, the availability of funds to complete product development plans and MediciNova’s ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova’s filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2025 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

INVESTOR CONTACT:

David H. Crean, Ph.D.
Chief Business Officer
MediciNova, Inc
info@medicinova.com

• First greenfield Enhanced Geothermal Systems (EGS) project synchronized to the grid and exporting electricity (First Power)
• Industry-leading milestone validates EGS as a scalable source of 24/7 carbon-free power
• Marks the first megawatts of a multi-gigawatt development, with 900 MW fully contracted and more than 4 GW of capacity

HOUSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) — Fervo Energy (Nasdaq: FRVO), a global pioneer of next-generation geothermal energy, today announced that Cape Station, its flagship geothermal development in Beaver County, Utah, has achieved First Power, marking the first time a utility-scale enhanced geothermal development has reached this milestone anywhere in the world.

The achievement comes just over four months after Fervo’s May 2026 initial public offering and is one of several industry leading operational milestones for the company. Following the successful deployment of Fervo’s EGS technology at Project Red, which has been supplying electricity to the grid since 2023, First Power at Cape Station represents a significant scale-up of the technology in a greenfield setting. With this milestone, the company converts years of subsurface and surface development, drilling, and project financing into an operating power plant selling electricity to the grid.

“This is a gamechanger for the geothermal industry. It establishes EGS as the defining new power generation technology of our time and we believe it shows that the commercial and technical maturity of EGS is ready to meet the urgent need for reliable, clean power,” said Tim Latimer, CEO and Co-Founder of Fervo Energy. “I could not be more proud of the years of hard work from Fervo’s employees, investors, suppliers, customers, and partners, which brought us to this moment. We are just getting started.”

Cape Station Details

Cape Station Phase I is an approximately 100 MW installation comprising three 33-megawatt GeoBlocks, the first of which has achieved First Power and is expected to reach its contractual commercial operations date (COD) by October 1, 2026. Fervo will continue ramping up the first GeoBlock as it brings the full well system online while commissioning the remaining two GeoBlocks, which are expected to reach contractual COD by January 1, 2027. The next phase, an additional 400 MW, is already under construction, with an expected COD in 2028. Fully contracted offtake at Cape Station sits at approximately 900 MW, enough to power the equivalent of nearly 1 million U.S. homes annually.

Fervo uses horizontal drilling techniques adapted from the oil and gas industry, allowing multiple wells to be drilled from a single pad and unlocking geothermal resources that were previously inaccessible with traditional technology.

“Cape Station works because we treated the subsurface like an engineering challenge,” said Jack Norbeck, Chief Technology Officer and Co-Founder of Fervo Energy. “Years of drilling, completion design, subsurface modeling, and flow testing led to this moment, and this is the validation that matters most. First Power is proof the science works.”

24/7 Firm Power

Enhanced geothermal draws continuously on heat deep underground, producing electricity around the clock regardless of weather or time of day. That makes it one of the only carbon-free resources capable of delivering firm, always-on power, a critical advantage as data centers, AI infrastructure, and reshored manufacturing drive the fastest growth in U.S. electricity demand in decades. 

Geothermal plants also require a comparatively small surface footprint relative to their output, produce zero operational emissions, and draw on a domestic and largely U.S.-based supply chain.

About Fervo Energy

Fervo Energy (Nasdaq: FRVO) is a modern power company built around one of the market’s most important needs: affordable, dependable new power supply. Through the large-scale deployment of enhanced geothermal systems, Fervo has established a repeatable, industrial approach to building utility-scale power. The company is transforming geothermal into a clean, reliable, cost-competitive solution designed to meet rising demand from AI hyperscalers, utilities, and a more electricity-intensive economy. For more information, visit www.fervoenergy.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, which involve risks, uncertainties, and assumptions. All statements, other than statements of historical fact, are forward-looking statements. When used in this press release, the words “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “guidance,” “intend,” “may,” “model,” “outlook,” “plan,” “positioned,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions (including the negative of such terms) are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Although Fervo believes that the expectations and assumptions reflected in its forward-looking statements are reasonable as and when made, they involve risks and uncertainties that are difficult to predict and, in many cases, beyond Fervo’s control. Accordingly, forward-looking statements are not guarantees of future performance, and Fervo’s actual outcomes could differ materially from what Fervo has expressed in its forward-looking statements.

Factors that could cause the outcomes to differ materially include (but are not limited to) the following: risks related to expanding our geothermal operations and accessing new markets; challenges in maintaining compliance with extensive environmental regulations and permitting requirements; uncertainties in forecasting future operational results and growth due to economic conditions and market demand; compliance with environmental regulations and climate change initiatives impacting operational costs; inherent risks in the geothermal industry, including potential operational disruptions and associated liabilities; the influence of consumer preferences, government policies, and competition on the demand for geothermal energy; risks associated with fluctuations in energy prices and material costs; dependence on a complex supply chain and successful maintenance of our geothermal infrastructure; financial performance influenced by fluctuations in interest rates, capital availability, and other market conditions; capacity actually constructed or for which we enter power purchase agreements under non-binding agreements, like the Geothermal Framework Agreement; exposure to legal proceedings and claims arising from our business operations; protecting our brand reputation and facing potential negative public perception; negative public perception and political opposition impacting our ability to secure regulatory approvals and market acceptance; the successful and timely execution of our growth strategy, with risks of delays or failures; reliance on key personnel and the potential impact of labor costs and workforce challenges; heavy reliance on technology systems and potential cybersecurity threats; global economic and political conditions affecting our operations, supply chain, and customer demand; the risk that our estimates of capacity potential and heat initially in place are inaccurate or that we are unable to produce quantities of electrical energy commensurate with such estimates; and other risks and uncertainties, including those set forth under “Risk Factors” in Fervo’s Registration Statement on Form S-1/A, filed with the Securities and Exchange Commission (the “SEC”) on May 11, 2026, and Fervo’s other filings with the SEC.

In light of these factors, the events anticipated by Fervo’s forward-looking statements may not occur at the time anticipated or at all. Moreover, Fervo operates in a very competitive and rapidly changing environment, and new risks emerge from time to time. Fervo cannot predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those anticipated by any forward-looking statements it may make. Accordingly, you should not place undue reliance on any forward-looking statements. All forward-looking statements speak only as of the date of this press release or, if earlier, as of the date they were made. Fervo does not intend to, and disclaims any obligation to, update or revise any forward-looking statements unless required by applicable law.

Contact

V2 Communications for Fervo Energy

fervo@v2comms.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1bd4d1a1-0e84-4870-aac0-b0a93bde091e

HOUSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) — KBR (NYSE: KBR) is pleased to welcome Michael LaRouche on his first day as President and Chief Executive Officer-Designate of Trinzic, the planned spin-off of KBR’s Mission Technology Solutions business. Michael will shape the strategic direction, accelerate growth and drive performance for Trinzic, which is expected to launch on January 4, 2027, as a publicly traded global company. Trinzic is backed by decades of experience on the highest-priority national security and space missions and will deliver technology-forward solutions to governments, partners and allies worldwide.

“We’re building Trinzic on an incredible foundation of deep technical capabilities, mission expertise and the trust of our customers to perform when there is no margin for error,” LaRouche said. “I’m excited to work alongside our talented teams around the world to shape Trinzic’s future, with a shared focus on moving with greater agility, embracing innovation and creating even more value for our customers and shareholders.”

Trinzic will employ 18,000 engineers, scientists and other domain experts who are embedded in the programs they serve or stationed at the company’s 60 locations around the world. LaRouche is based in the company’s principal executive office in Arlington, Virginia. Trinzic’s significant footprint in Washington, D.C. allows for close engagement with policymakers and enables collaboration with the Pentagon and intelligence community customers, helping them navigate complexity and make decisions with confidence.

As an independent company, Trinzic will have more than $5 billion in revenue and a diverse portfolio spanning integrated air and missile defense, human performance, global operations, space exploration and space domain awareness. LaRouche will oversee the company’s strategy and execution, drawing on three decades of experience gained through senior leadership roles at Serco, SAIC, Raytheon and Lockheed Martin.

In anticipation of the planned spin-off, KBR also announced that Gabe Butler will join the company on October 5 as Vice President-Designate of Investor Relations for Trinzic. Butler brings more than 14 years of experience across program finance, investor relations and Financial Planning and Analysis (FP&A). He most recently served as Director of FP&A for the Government Operations segment at BWX Technologies and previously held finance and investor relations leadership roles at Leidos.

Butler will play a key role in preparations for and execution of Trinzic’s inaugural Investor Day on November 12 in New York City. Trinzic’s executive leadership team will provide additional details on its strategic vision, growth strategy and financial outlook at the event.

The planned spin-off is intended to be tax-free to KBR and its shareholders for U.S. federal income tax purposes and remains subject to customary conditions, including regulatory approvals and final approval by KBR’s Board of Directors. Following the spin-off, New KBR will continue to be led by Stuart Bradie and will encompass the company’s Sustainable Technology Solutions business.

About KBR
KBR is a global, capital-light lifecycle solutions company serving customers in high-complexity industrial, energy and infrastructure markets. Through its advisory, technical, engineering and operating expertise, KBR helps customers shape investments, reduce risk, deploy complex technologies, improve performance and deliver reliable outcomes across the asset lifecycle. 

Following the planned separation of the Mission Technology Solutions business, KBR will operate as a focused standalone company with differentiated customer relationships, global execution capabilities and a capital-efficient business model. The company is positioned to benefit from long-term secular growth trends across energy security, energy transition, industrial modernization, and infrastructure investment. KBR’s 15,000 employees operate across more than 40 countries. 

Visit www.kbr.com

About Trinzic
KBR’s Mission Technology Solutions business is expected to be spun off as an independent public company in January 2027 and will then operate under the new name Trinzic. The name is inspired by the word intrinsic, reflecting the essential capabilities, deep expertise, speed and trusted performance that have defined the business for decades. Trinzic will enter the market as a global company and partner to customers supporting some of the highest priority missions across national security, human performance, global operations and space. Trinzic will launch with more than $5 billion in annual revenue, established partnerships and contracts, 18,000 employees and a global footprint.

Forward Looking Statements
The statements in this press release that are not historical statements, including statements regarding the spin-off KBR’s Mission Technologies Solutions business and future performance of SpinCo and KBR, are forward-looking statements within the meaning of the federal securities laws. These statements are subject to numerous risks, uncertainties and assumptions, many of which are beyond the company’s control, that could cause actual results to differ materially from the results expressed or implied by the statements. These risks, uncertainties and assumptions include, but are not limited to, those set forth in the company’s most recently filed Annual Report on Form 10-K, any subsequent Form 10-Qs and 8-Ks and other U.S. Securities and Exchange Commission filings, which discuss some of the important risks, uncertainties and assumptions that the company has identified that may affect its business, results of operations and financial condition. Due to such risks, uncertainties and assumptions, you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Except as required by law, the company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

For further information, please contact:

Investors
Rachael Goldwait
Vice President, Investor Relations
713-753-5082
Investors@kbr.com

Media
Philip Ivy
Vice President, Global Communications and Marketing
713-753-3800
MediaRelations@kbr.com

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/d758e5a2-12c4-4080-a53a-45695296e545
https://www.globenewswire.com/NewsRoom/AttachmentNg/534f2854-e7a1-4c68-8012-f85bafb40d30

Global Phase 3 study will evaluate efzofitimod in patients with pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint.

Company expects to initiate study-related activities in the fourth quarter of 2026.

SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of its lead therapeutic candidate, efzofitimod, in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The Company expects to focus on regulatory submissions in the U.S. and Europe as it initiates study-related activities in the fourth quarter of 2026.  

“We received feedback earlier this week from the FDA and we are very pleased to have reached alignment on the protocol for our planned Phase 3 study of efzofitimod in pulmonary sarcoidosis, a major form of interstitial lung disease,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr Pharma. “This important milestone reflects the progress of our efforts to advance efzofitimod for patients with pulmonary sarcoidosis. With limited treatment options available, particularly for patients requiring chronic therapy, we believe efzofitimod has the potential to become an important new treatment option.”

The planned Phase 3 trial will be a global, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of efzofitimod in patients with moderate to severe pulmonary sarcoidosis. The 54-week study will consist of two parallel cohorts randomized equally to either 5.0 mg/kg efzofitimod or placebo dosed intravenously once every 3 weeks for a total of 17 doses. The study is intended to enroll up to approximately 372 patients with symptomatic pulmonary sarcoidosis with restrictive lung disease who are receiving a stable dose of ≤ 5.0 mg daily oral corticosteroid and/or a background immunosuppressant. All background treatment will remain stable throughout the duration of the study. The primary endpoint of the study will be change from baseline in forced vital capacity (FVC) at week 48 and the key secondary endpoint will be change from baseline in the King’s Sarcoidosis Questionnaire (KSQ)-Lung score at week 48.

The study design is supported by data from a subgroup analysis of the Phase 3 EFZO-FIT™ study that showed that patients with pulmonary sarcoidosis with restrictive lung disease (defined as FVC percent predicted ≤ 80% with a normal FEV1/FVC ratio) who were treated with 5.0 mg/kg efzofitimod experienced a clinically meaningful benefit in FVC and improvements in multiple patient-reported outcomes, including the KSQ-Lung score, compared to placebo. These findings were presented at the World Association of Sarcoidosis and Other Granulomatous Disorders 2026 Congress.

Future development of efzofitimod in the planned Phase 3 study in pulmonary sarcoidosis will require the Company to obtain additional capital through equity or debt offerings, grant funding, collaborations, strategic partnerships and/or licensing arrangements.

About Efzofitimod

Efzofitimod is a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 to resolve inflammation without immune suppression and potentially prevent the progression of fibrosis. Efzofitimod is currently being investigated in the Phase 2 EFZO-CONNECT™ study in patients with systemic sclerosis (SSc, or scleroderma)-related ILD,   and aTyr plans to initiate study-related activities for a global Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis, a major form of ILD, in the fourth quarter of 2026. These forms of ILD have limited therapeutic options and there is a need for safer and more effective, disease-modifying treatments that improve outcomes.

About aTyr

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually identified by the use of words such as “anticipate,” “believes,” “can,” “could,” “designed,” “expects,” “intends,” “may,” “plans,” “potential,” “upcoming,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include, among others, statements regarding our continued development of efzofitimod in pulmonary sarcoidosis, including the additional capital that we expect to be necessary for future development; timelines and plans with respect to certain regulatory and development milestones, activities and goals, including our plans to initiate study-related activities in the fourth quarter of 2026 for the planned Phase 3 study; the proposed design of our planned Phase 3 study of efzofitimod in pulmonary sarcoidosis, including the dosing regimen, enrollment expectations, targeted endpoints, and strategy to focus on a more limited patient population; and our interpretation of the results of the Phase 3 EFZO-FIT™ study and the meaning of those interpretations for our planned Phase 3 study. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations, strategies or prospects will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, uncertainty related to interactions with the FDA in general, risks that the results from the planned Phase 3 study may not ultimately support FDA approval of efzofitimod in pulmonary sarcoidosis, uncertainty regarding geopolitical and macroeconomic events, risks associated with the discovery, development and regulation of efzofitimod, the risks associated with targeting a more limited patient population in our planned Phase 3 study of efzofitimod in pulmonary sarcoidosis, the risk that we or future partners may cease or delay preclinical or clinical development activities for efzofitimod for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the possibility that future collaborations could be terminated early, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Ashlee Dunston
Sr. Director, Investor Relations and Public Affairs
adunston@atyrpharma.com

TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) — Blossom Gold Inc. (formerly, 1290448 B.C. Ltd.) (“Blossom” or the “Company”) (TSX: BGAU) is pleased to announce further drill results from its ongoing 2026 exploration program at the Rosebud Open-Pit Heap-Leach Project (“Rosebud” or the “Project”) in Pershing County, Nevada. This release builds on exploration results reported on June 30, 2026 and August 12, 2026 and highlights continued expansion and infill success across the South, East and Northwest Zones.

Highlights

• South Zone: Thick gold mineralization continues to surround the historic south mined zones and extend up-dip along the South Ridge Fault Zone. BG26-031 intersected 44.8m @ 1.22gAu/t from 149.8m, including 3.2m @ 5.06gAu/t from 181.8m.
• Near-surface oxide: RC26-009 intersected 60.1m @ 0.33gAu/t from surface, including 19.6m @ 0.68gAu/t from 40.5m, and RC26-010 intersected 14.6m @ 0.24gAu/t in the oxidized domain of the South Zone.
• East Zone: BG26-042 intersected 106.8m @ 0.42gAu/t from 74.8m, including 24.2m @ 0.72gAu/t from 156.0m. This supports a broad halo of gold mineralization around the historic mine workings.
• Maiden Northwest Zone hole: BG26-033 intersected 18.5m @ 0.20gAu/t from 38.9m, starting at the upper bedrock contact. This may be part of a shallow zone of mineralization extending across the north part of the deposit.
• Program update: Four rigs are operating, with 11,585m (38,000 ft) remaining in the 2026 surface program. The 8,230m (27,000 ft) underground infill program is expected to begin in Q4 2026, and an updated Mineral Resource Estimate is expected in Q1 2027.

“The Blossom exploration program is picking up the pace, with 19,911m of drilling completed so far this year. Our third batch of results continues to demonstrate the scale of the mineralized system at Rosebud, both around the historic workings and in the areas the underground operation left behind,” said Rick Winters, CEO of Blossom Gold. “In the South Zone, BG26-031 returned 44.8m @ 1.22gAu/t, including 3.2m @ 5.06gAu/t, confirming thick gold mineralization around the historic south mined zones. Closer to surface, our reverse circulation drilling delivered as well, with RC26-009 intersecting 60.1m @ 0.33gAu/t from surface in oxidized material. That is the kind of near-surface mineralization our open-pit, heap-leach vision is built on. In the East Zone, BG26-042 intersected 106.8m @ 0.42gAu/t, further defining the broad halo of mineralization around the old mine. Our first hole in the Northwest Zone also found gold mineralization starting at the upper bedrock contact, which points to a potential shallow zone across the north part of the deposit.”

“We have four rigs turning 24/7, with 11,585m of surface drilling remaining in the 2026 program. Rehabilitation of the underground portal is on track to establish drill bays and begin the 8,230m underground infill program in the fourth quarter. Together, these programs will inform the updated Mineral Resource Estimate we expect to deliver in the first quarter of 2027,” added Mr. Winters.

Technical drilling for permitting and design work is now 100% complete, with expansion resource drilling the focus of the ongoing program. Three core drill rigs and one RC rig remain devoted to drilling aimed at expanding and upgrading the existing inferred open-pit resource of 70.8 million tons at 0.018opt Au (0.62gAu/t) and 0.189opt Ag (6.49gAg/t) for 1.28 million ounces of gold and 13.4 million ounces of silver (see About Blossom Gold section below for more information).

In the South Zone, results from diamond drill holes BG26-031, -041, and RC drill holes RC26-009 and -010 combined with previously reported South Zone drill holes, confirm that significant thicknesses of gold mineralization surround the historic south mined zones and continue up-dip along the South Ridge fault zone, with gold grade extending to or near the top of bedrock. The oxidized domain extends to depths ranging from 20-75 meters below the surface.

In the East Zone, results from diamond drill holes BG26-039 and -042, together with previously reported East Zone drill holes, support the presence of a broad halo of gold mineralization surrounding historic mine workings and extending south and westwards along strike towards the South Zone. Gold mineralization intercepted by these two drill holes is in the non-oxidized domain.

Diamond drill hole BG26-033 targeted the Northwest Zone and indicates there is a zone of gold mineralization starting at the upper bedrock contact. These results are similar to previously reported results from Site T in the Northeast Zone and may represent a shallow zone of mineralization extending across the north part of the deposit. Additional recent drilling from Site M of hydrothermally altered and mineralized rocks suggests this zone may extend to the northwest of BG26-033. Assay results for drill holes from Site M are pending.

Figure 1 – Rosebud Open-Pit Drilling Zones with Recent Drill Hole Locations

* Mined zones represent stope and backfilled areas from 1997 to 2000 during the Hecla/Newmont Joint Venture operations. The Joint Venture mined just under one million tons at 0.44opt Au (15gAu/t).
Source: Blossom Gold Inc.

“Drilling of the up-dip South Ridge fault zone targets is showing two zones of gold mineralization each hosted by dacite flows and breccia” stated Dr. John DeDecker, VP, Exploration of Blossom. “The upper zone is in the oxidized domain and is near-surface, and the lower zone is higher grade, in the non-oxidized domain, and occurs at depth surrounding the historic mine workings. The presence of elevated gold grades in dacite is consistent with the interpretation by the former mine geologists that coherent volcanic rocks are more susceptible to fracturing and vein formation than strongly clay and chlorite altered fine-grained tuffaceous rocks are.”

As previously noted, drill hole assay results are reported by zone over the approximately 2km by 1.6km open pit target; the Northwest, Northeast, Southwest, South, and East Zones, as illustrated in Figure 1. In the East and South Zones, the target is up dip extension of South Ridge Fault Zone (SRFZ) mineralization above the previously mined orebodies in areas of low drill density owing to the historic focus on high grade underground mineralization. The Northeast and Northwest zones are in the Rosebud Shear Zone with low, historic drill density. Expansion drilling in these zones target the potential to add resource and push the resource pit shell to the north. The Southwest Zone is also in the Rosebud Shear Zone domain and targets areas of low drill density to potentially expand the open pit resource to the property boundary in the southwest of the Rosebud claims.

Drill hole inclination is taken into account to determine the true thickness of mineralized intervals from surface. All intervals Blossom reports will be true thicknesses unless otherwise noted. Only gold values are reported. In-situ, the silver to gold ratio at Rosebud is 10:1 based on the 43-101 technical report as well as historic production, adjusted for recoveries. However, Blossom will report gold only as opposed to gold equivalent results until such time the Company has better information on forecast silver recoveries from the ongoing metallurgical testing.

Rosebud Open Pit Expansion and Infill Drilling
Determined at a 0.005opt (0.17gAu/t) cutoff grade, highlighted > 0.01opt (0.34 gAu/t);
Hole Type – E = Expansion/Exploration, I = Infill, M = Metallurgical, GT = Geotechnical, GC = Geochemical

South Zone

Hole ID	Pad	Type	Dip	From	T	From	To	True Thickness		Au	Au
				ft	ft	M	m	ft	m	opt*	g/t
BG26-031	O	E	–55	491.4	638.3	149.8	194.6	146.9	44.8	0.036	1.224
Including				498.3	539.7	151.9	164.5	41.4	12.6	0.055	1.882
Including				580.6	606.7	177.0	185.0	26.1	8.0	0.076	2.620
Including				596.2	606.7	181.8	185.0	10.5	3.2	0.148	5.064
BG26-041	R	GC	-45	28.6	227.6	8.7	69.4	198.9	60.7	0.006	0.215
Including				166.0	208.6	50.6	63.6	42.6	13.0	0.011	0.365
RC26-009	R	E	-80	0.0	197.1	0.0	60.1	197.1	60.1	0.010	0.327
Including				133.0	197.1	40.5	60.1	64.1	19.6	0.020	0.682
RC26-009	R			389.2	408.9	118.6	124.7	19.7	6.0	0.013	0.440
RC26-009	R			433.5	463.1	132.2	141.2	29.6	9.0	0.014	0.472
RC26-010	R	E	-60	90.5	138.3	27.6	42.2	47.8	14.6	0.007	0.244
RC26-010	R			403.7	455.9	123.1	139.0	52.2	15.9	0.005	0.174
RC26-010	R			512.7	591.7	156.3	180.4	79.0	24.1	0.009	0.312

East Zone

Hole ID	Pad	Type	Dip	From	T	Fro	T	True Thickness		Au	Au
				ft	ft	M	m	ft	m	opt*	g/t
BG26-039	S	GT	-75	161.7	550.2	49.3	167.7	388.5	118.4	0.007	0.252
	Including			166.5	237.8	50.8	72.5	71.3	21.7	0.011	0.394
	Including			325.3	364.9	99.2	111.2	39.6	12.1	0.010	0.337
BG26-039	S			608.4	660.5	185.5	201.4	52.1	15.9	0.008	0.283
BG26-039	S			680.0	702.2	207.3	214.1	22.2	6.8	0.010	0.344
BG26-039	S			717.7	752.2	218.8	229.3	34.4	10.5	0.009	0.314
BG26-042	S	E	-55	245.5	595.7	74.8	181.6	350.2	106.8	0.012	0.419
Including				390.3	464.8	119.0	141.7	74.5	22.7	0.017	0.575
Including				511.6	590.9	156.0	180.1	79.3	24.2	0.021	0.716
BG26-042	S	E	-55	628.8	653.8	191.7	199.3	25.0	7.6	0.008	0.291

Northwest Zone

Hole ID	Pad	Type	Dip	From	T	From	To	True Thickness		Au	Au
				ft	ft	M	m	ft	m	opt*	g/t
BG26-033	A	GT	-85	127.6	188.3	38.9	57.4	60.8	18.5	0.006	0.200

* Grade is capped at 6.8gAu/t in holes BG26-031 and BG26-042 with three assays capped.
* opt calculated from g/t using a conversion factor of 1 opt equals 34.286gAu/t and rounded off to the third decimal.

Blossom Gold continues to advance the 2026 Rosebud exploration program, which includes continued surface drilling with four drill rigs with a priority on resource expansion and infill holes going forward, though technical drilling will also be scheduled as needed in support of the Project’s Plan of Operations, Environmental Impact Statement and Feasibility Study. To date, the Company has drilled 19,911 meters of the planned 31,496-meter surface drilling campaign.

About Blossom Gold Inc.

Blossom is a Canadian-based precious metals exploration and development company that recently began trading on the TSX under the symbol BGAU. Blossom acquired the Rosebud Project in connection with the TSX-listing and will be focused on the exploration and development of the project. The Rosebud Project includes the former Rosebud Mine, where mining was conducted from 1997 through 2000 by the Rosebud Mining Company, a Newmont-Hecla joint venture, using underground mining methods where the mine operated at a cut-off grade of approximately 0.2 opt Au (6.8 gAu/t), when gold prices ranged from US$250 to US$350/oz; with mined material truck-hauled approximately 120 miles to an existing Newmont oxide mill for processing.

The current vision for the Rosebud Project is to evaluate the remaining higher-grade mineralization and the surrounding larger volume of lower grade mineralization as a potential open pit mining operation with on-site, heap-leach processing and recovery of gold and silver. The Rosebud Project currently hosts an Inferred Mineral Resource of 70.755 million tons grading 0.62gAu/t (0.018opt Au) and 6.49gAg/t (0.189opt Ag) for 1.28 million ounces of gold and 13.4 million ounces of silver. The mineral resource estimate was open pit constrained using long term gold and silver prices of US$2,500 and US$35 per ounce respectively. The deposit is open in all directions.

Further details on Blossom and the Rosebud Project, including the technical report titled “Mineral Resource Estimate for the Rosebud Property, Pershing County, NV, USA” by Northern Lights Mining LLC, with a report date of December 17, 2025 and an effective date of November 1, 2025, can be found under the Company’s profile on SEDAR+ at www.sedarplus.com and the Company’s website at www.blossomgold.com.

Qualified Person

The scientific and technical information contained in this news release has been reviewed and approved by Dino Titaro, P.Geo., a Director of Blossom who is a Qualified Person as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects.

Quality Assurance/Quality Control (QA/QC)

Core from the field is logged, photographed and cut with halved drill core samples bagged and sealed for pick-up by MSALABS in Elko, Nevada for preparation and analysis. MSALABS is accredited to ISO 17025 standards for gold and silver assays. All analytical methods include quality control standards and blanks inserted at set frequencies. The entire sample interval is crushed and homogenized with 500 g of the homogenized sample pulverized for photon assay of gold and silver (detection limits: 0.025 g/t Au and 3.7 g/t Ag). Every five holes the photon results are confirmed by complete chemical analysis at MSALABS in Vancouver to provide QA/QC checks on the photon assays as well as provide full chemical analysis of the sample. QA/QC checks consist of gold fire assay of a 50 g sample followed by ICP-ES finish, and aqua regia digestion of a 40 g sample followed by ICP-ES and ICP-MS for analysis of silver (detection limit: 0.05 g/t) and gold-pathfinder element concentrations.

For further information, please contact:

Brandon Throop
Vice President, Corporate Development & Investor Relations
Direct: 1-647-646-7824
Email: bthroop@blossomgold.com

Cautionary Statement on Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. All statements other than statements of historical facts included in this news release constitute forward-looking information, including but not limited to statements regarding the Company’s plans, prospects and business strategies, including its senior leadership team, its core drilling program and advancing the Rosebud Project, permitting and commencing construction, and its vision regarding the Rosebud Project. Terminology such as “plan”, “expect”, “schedule”, “estimate”, “forecast”, “intend”, “anticipate”, “believe”, “may” or “will” and similar expressions identify forward-looking information. By identifying such information in this manner, Blossom is alerting the reader that such information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Blossom to be materially different from those expressed or implied by such information. In addition, in connection with the forward-looking information contained in this news release, Blossom has made certain assumptions. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the inability of Blossom to achieve any one or more of the key catalysts on the timeline expected, or at all, and any changes in the development of the business of Blossom, as well as those risk factors more generally set out in Blossom’s AIF, which is available under Blossom’s profile on SEDAR+ at www.sedarplus.com. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein. Although Blossom believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information are reasonable, undue reliance should not be placed on such information, and no assurance or guarantee can be given that such forward-looking information will prove to be accurate. The forward-looking information contained in this news release is provided as of the date of this news release, and Blossom does not undertake to update any forward-looking information that is contained or referenced herein, except in accordance with applicable Canadian securities laws.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/64757e93-db11-4a33-8a63-6984fa72d570

https://www.globenewswire.com/NewsRoom/AttachmentNg/69b75a63-2dc5-4735-b3d2-778d25253687

HONG KONG, Sept. 24, 2026 (GLOBE NEWSWIRE) — TJGC Group Limited (NASDAQ: TJGC) (“TJGC” or the “Company”) today announced that its Board of Directors has authorised a share repurchase program for up to US$2,000,000 of the Company’s Class A ordinary shares.

“The adoption of this share repurchase program reflects the Board’s confidence in the Company’s long-term strategy and growth prospects, as well as our commitment to a disciplined approach to capital allocation. We believe this program provides us with the flexibility to return capital to our shareholders in a manner that enhances shareholder value, while preserving our ability to invest in the growth of our business,” said Bin Guo, Chief Executive Officer and a director of the Company.

Under the program, the Company may make repurchases, from time to time, through open market purchases, block trades, in privately negotiated transactions, or by other means. Open market repurchases will be structured to occur in accordance with applicable federal securities laws, including within the pricing and volume requirements of Rule 10b-18 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company may also, from time to time, enter into Rule 10b5-1 plans to facilitate repurchases under this authorisation. The volume, timing, and manner of any repurchases will be determined at the Company’s discretion, subject to general market conditions, as well as the Company’s management of capital, general business conditions, other investment opportunities, regulatory requirements, and other factors. The repurchase program does not obligate the Company to repurchase any specific amount of Class A ordinary shares, has no time limit, and may be modified, suspended, or discontinued at any time without notice at the discretion of the Board of Directors. The Company currently expects to fund the repurchase program from existing cash and cash equivalents and/or future cash flows.

About TJGC Group Limited

TJGC Group Limited, through its subsidiary, Ctrl Media Limited provides integrated marketing and advertising services in Hong Kong. The company offers services to mobile game developers, principally developers of mobile gaming applications that gamers download from the developers’ websites and applicable mobile operating systems, such as Apple Store or Android Google Play Store. It also uses digital media, such as online social media platforms, websites, and search engines over the Internet to broadcast the advertising campaigns. In addition, the company undertakes contracts with YouTuber, KOL, and local celebrities to film introductory gaming videos for broadcast in their personal blogs and social media platforms; offers physical media, including podium platforms with transportation terminals and public venues to broadcast advertising campaigns; and assists clients to plan and prepare their exhibition booths in the animation-comic-game and other offline marketing events. The company was formerly known as Ctrl Group Limited and change its name to TJGC Group Limited in November 2025. TJGC Group Limited was incorporated in 2022 and is based in Hung Hom, Hong Kong.

Forward-Looking Statements

Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the timing, volume and manner of any repurchases under the share repurchase program and the funding thereof. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the Company’s registration statements filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and TJGC specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

For more information, please contact:

Investor Relations
Ctrl Media Limited
Phone: +852-3107-4887
Email: project@ctrl-media.com

Biodesix-led tumor-informed and tumor-naïve programs draw on the company’s bioinformatics and diagnostics test development expertise

LOUISVILLE, Colo., Sept. 24, 2026 (GLOBE NEWSWIRE) — Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced strategic progress in two collaborative programs for tumor-informed and tumor-naïve Molecular Residual Disease (MRD) solutions intended to support cancer centers and clinical laboratories. Both solutions detect circulating tumor DNA (ctDNA), the tumor DNA that a cancer sheds into the blood, to assess whether disease remains or is returning after treatment. The tumor-informed solution is the result of a multi-year collaboration with Bio-Rad Laboratories. The tumor-naïve solution is a newly launched program with Thermo Fisher Scientific that extends a collaboration for companion diagnostic validation and other development work. Both approaches will be validated by Biodesix in collaboration with key investigators at Memorial Sloan Kettering Cancer Center (MSK) and are designed to run on partner platforms already installed in laboratories around the world.

“Our approach to MRD reflects a core conviction: sensitivity matters, and so does patient access. We are building ultra-sensitive assays with global collaborators whose platforms can carry those assays to laboratories and patients around the world,” said Scott Hutton, Chief Executive Officer of Biodesix. “Offering both tumor-informed and tumor-naïve MRD means the clinical question can drive the testing strategy, rather than forcing a single approach in every situation. We believe this work positions Biodesix to participate in the growth of MRD testing well beyond the patients that can be reached through a centralized laboratory model.”

No single MRD approach serves every patient. Tumor-informed testing is generally the most sensitive option when tumor tissue is available, and tumor-naïve testing extends monitoring to patients whose tissue is unavailable or insufficient. Biodesix is advancing both, drawing on its proprietary Diagnostic Cortex^® bioinformatics platform, its experience developing, validating, and commercializing diagnostic tests in its CAP-accredited, CLIA- and NYS CLEP-certified laboratory, and its track record in companion diagnostics test validation with global partners. The two programs build on MRD data that Biodesix and its collaborators have presented at scientific meetings over the past two years. Together they represent the first time Biodesix has outlined its MRD strategy as a whole and represents an expansion of the company’s focus beyond lung diagnostics into a rapidly growing area of precision oncology.

Tumor-informed MRD

For the tumor-informed solution, Biodesix profiles a patient’s tumor tissue using its proprietary Diagnostic Cortex^® bioinformatics platform to identify multiple complex genomic changes unique to that individual. Bio-Rad’s Droplet Digital™ PCR technology is then used to track those changes in blood over the course of the patient’s care, partitioning each sample into thousands of separate reactions so that individual tumor molecules can be counted. The ultra-sensitive informatics and analysis workflows detect ctDNA below 1 part per million (ppm) of the total DNA in a blood sample.

“Detecting molecular residual disease means finding a handful of molecules in a complex background, the precise application for which Droplet Digital PCR has an advantage over other technologies. Our multi-year work with Biodesix has focused on making that sensitivity practical in routine laboratories. We look forward to supporting broad access to these solutions and the positive impact they will have on patient lives,” said Steve Kulisch, Vice President of Genomics Product Management, Bio-Rad Laboratories.

Tumor-naïve MRD

The tumor-naïve solution detects methylated ctDNA in blood using rapid next-generation sequencing on the Genexus™ platform from Thermo Fisher Scientific. Biodesix has begun developing and validating this assay in its CAP-accredited, CLIA- and NYS CLEP-certified laboratory as part of the Thermo Fisher Center of Excellence Network. Because the method reads methylation patterns rather than mutations unique to an individual tumor, it requires no tumor tissue. This means the test can potentially help patients who otherwise would not have been eligible for an MRD test because their archived tissue is unavailable or insufficient.

“Methylation carries a rich biological signal, and rapid analytic and informatics workflows make it possible to act on that signal in a clinically relevant timeframe,” said Gary Pestano, Ph.D., Chief Scientific Officer of Biodesix. “By providing both tumor-informed and tumor-naïve approaches, Biodesix can reach more of the patients who may benefit from molecular monitoring throughout their cancer journey.”

Upcoming presentations

Gary Pestano, Ph.D., Chief Scientific Officer of Biodesix, will join a spotlight panel on the future of MRD at the 5th Annual Roth Healthcare Opportunities Conference.

Panel Title: The Rise of MRD Monitoring in Solid Tumors and Where it Goes Next
Date and Time: Tuesday, September 29, 2026, 2:00 PM ET
Location: The Metropolitan Club, New York, NY
Panelists:

• Gary Pestano, Ph.D., Chief Scientific Officer, Biodesix, Inc. (Nasdaq: BDSX)
• Amal Thommil, MRD Monitoring Specialist, DeciBio
• Pedram Razavi, M.D., Ph.D., Medical Oncologist, Director of Liquid Biopsy & Cancer Genomics, MSK

Data supporting both MRD programs will be presented at the AMP 2026 Annual Meeting in November 2026 in Seattle, with additional data planned for the San Antonio Breast Cancer Symposium in December 2026. The presentations will feature continued collaborative work with MSK, Bio-Rad Laboratories, and Thermo Fisher Scientific.

Notes and Disclosures:

Memorial Sloan Kettering (MSK) has institutional financial interests related to Biodesix, Inc.

Droplet Digital PCR is a trademark of Bio-Rad Laboratories, Inc.

Genexus is a trademark of Thermo Fisher Scientific.

Nodify Lung, IQLung, and Diagnostic Cortex are registered trademarks of Biodesix, Inc.

About Biodesix

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung^® Nodule Risk Assessment and IQLung^® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. Visit biodesix.com for more information.

Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning possible or assumed future results of operations, including descriptions of our revenues, profitability, outlook, and overall business strategy, the timing and assumptions regarding collection of revenues on projections, availability of funds and future capital, the anticipated impact and benefits of new clinical data, reimbursement coverage and research partnerships, the impact of enhanced U.S. tariffs, import/export restrictions or other trade barriers on the company and its operations and financial performance. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of our most recent Annual Report on Form 10-K, filed February 26, 2026, or subsequent Quarterly Reports on Form 10-Q during 2026, as applicable. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.

Contacts

Media: Natalie St. Denis, Director Corporate Communications, Biodesix
natalie.stdenis@biodesix.com | (720) 925-9285

Investors: Chris Brinzey, Partner, ICR
chris.brinzey@icrhealthcare.com | (339) 970-2843

Transaction in Own Shares

September 23, 2026

• • • • • • • • • • • • • • • •

Shell plc (the ‘Company’) announces that on 23 September 2026 it purchased the following number of Shares for cancellation.

Aggregated information on Shares purchased according to trading venue:

Date of Purchase	Number of Shares purchased	Highest price paid	Lowest price paid	Volume weighted average price paid per share	Venue	Currency
23/09/2026	600,000	£ 35.8200	£ 35.2650	£ 35.5626	LSE	GBP
23/09/2026	–	–	–	–	Chi-X (CXE)	GBP
23/09/2026	–	–	–	–	BATS (BXE)	GBP
23/09/2026	300,000	€ 41.7550	€ 41.1200	€ 41.4245	XAMS	EUR
23/09/2026	–	–	–	–	CBOE DXE	EUR
23/09/2026	–	–	–	–	TQEX	EUR

These share purchases form part of the on- and off-market limbs of the Company’s existing share buy-back programme previously announced on 30 July 2026.

In respect of this programme, Goldman Sachs International will make trading decisions in relation to the securities independently of the Company for a period from 30 July 2026 up to and including 23 October 2026.

The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market. The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein. The programme will be conducted in accordance with Chapter 9 of the UK Listing Rules and Article 5 of the Market Abuse Regulation 596/2014/EU dealing with buy-back programmes (“EU MAR”) and EU MAR as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020)  through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time (“UK MAR”) and the Commission Delegated Regulation (EU) 2016/1052 (the “EU MAR Delegated Regulation”) and the EU MAR Delegated Regulation as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time.

In accordance with EU MAR and UK MAR, a breakdown of the individual trades made by Goldman Sachs International on behalf of the Company as a part of the buy-back programme is detailed below.

Enquiries:

Media International: +44 (0) 207 934 5550; U.S. and Canada: https://www.shell.us/about-us/news-and-insights/media/submit-an-inquiry.html

Attachment

• 20260923_Shell RNS – full version

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Man Group PLC
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Senior Plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	23/09/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?	NO

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	10p ordinary
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:
(2)   Cash-settled derivatives:	10,620,439	2.53
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	10,620,439	2.53

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
10p ordinary	Equity Swap	Increasing a long position	8,951	2.9644 GBP

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii)        Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	24/09/2026
Contact name:	Molly Childs
Telephone number:	+44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.